Nrf2 activation for kidney disease treatment-a mixed blessing?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33390228.
- Also identified by DOI 10.1016/j.kint.2020.08.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activation of cellular antioxidative signaling is expected to be a silver bullet against kidney diseases, and clinical trials of compounds activating the antioxidant transcription factor Nrf2 have revealed their renoprotective effects. However, cardiac events have been observed in some cases with elevated urinary albumin excretion in these trials. Therefore, elucidating the negative effects of Nrf2 activation is essential. Rush and colleagues demonstrated that Nrf2 activation aggravates podocyte injury, a factor related to proteinuria and cardiac failure.
Medical subject headings
- Podocytes
- Renal Insufficiency, Chronic